BRTX:NSD-BioRestorative Therapies Inc. Common Stock (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 3.95

Change

0.00 (0.00)%

Market Cap

USD 0.01B

Volume

0.07M

Avg Analyst Target

USD 37.00 (+836.71%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


BioRestorative Therapies Inc. Common Stock (BRTX) Stock Analysis:
Based on the BioRestorative Therapies Inc. Common Stock stock forecasts from 1 analysts, the average analyst target price for BioRestorative Therapies Inc. Common Stock is USD 37.00 over the next 12 months. BioRestorative Therapies Inc. Common Stock’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of BioRestorative Therapies Inc. Common Stock is Very Bearish, which is based on 0 positive signals and 4 negative signals. At the last closing, BioRestorative Therapies Inc. Common Stock’s stock price was USD 3.95. BioRestorative Therapies Inc. Common Stock’s stock price has changed by -0.05% over the past week, -0.53% over the past month and -91.34% over the last year.

About

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/ ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-17 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

N/A

USD83.01B 12.27 12.33
REGN Regeneron Pharmaceuticals Inc

N/A

USD66.16B 9.84 8.23
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD59.51B 28.07 15.97
BNTX BioNTech SE

N/A

USD47.53B 6.14 5.67
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
SGEN Seagen Inc

N/A

USD25.07B 55.02 44.86
BGNE BeiGene Ltd

N/A

USD24.70B N/A N/A
GMAB Genmab A/S

N/A

USD23.58B 53.39 6.21
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
ALNY Alnylam Pharmaceuticals Inc

N/A

USD17.76B N/A N/A

ETFs Containing BRTX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -8.99% 53% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.99% 53% F 28% F
Trailing 12 Months  
Capital Gain -91.34% 1% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -91.34% 1% F 1% F
Trailing 5 Years  
Capital Gain -99.98% 1% F N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.98% 1% F N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 1,062.84% 99% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 1,062.84% 99% A+ 99% A+
Risk Return Profile  
Volatility (Standard Deviation) 2,444.31% 1% F 1% F
Risk Adjusted Return 43.48% 74% C 62% D-
Market Capitalization 0.01B 1% F 2% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -7.02 58% F 71% C-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 204.50% 99% A+ 99% A+
Return on Assets -803.03% 0% N/A 0% N/A
Debt to Equity Ratio -320.71% 98% A+ 97% A+
Technical Ratios  
Short Ratio 0.23 95% A 91% A-
Short Percent 6.27% 34% F 26% F
Beta 83.66 0% N/A 0% N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector